Hair Relaxer Settlement Amounts 2026: MDL 3060 Status & Claim Value

This hair relaxer settlement amounts 2026 guide starts with the fact that shapes everything else: no hair relaxer case has been settled or tried. Any figure presented as a hair relaxer payout is a projection. What follows sets out what the record actually contains, and what will determine claim value when the first numbers arrive.

Where the Litigation Actually Stands

Hair relaxer claims allege that manufacturers of chemical straightening products knew or should have known that repeated exposure to the chemicals in those products raised the risk of hormone-sensitive cancers, and failed to warn users.

The federal cases were consolidated into MDL 3060 in the Northern District of Illinois. The docket has grown substantially and is now among the largest active product-liability MDLs in the country. But volume is not the same as resolution, and the proceeding is still in its pretrial phase:

• Bellwether selection is complete — three cases have been designated to go first.
• Bellwether fact discovery closed in June 2026.
• Daubert and summary-judgment motions are due in November 2026. These will test whether the plaintiffs’ expert causation evidence is admissible — historically the point at which mass torts either gain momentum or collapse.
• First trials are expected in 2027.

Until those trials produce results, neither side has the information it would need to price a global settlement. That is why no matrix exists.

The Science the Claims Rest On

The litigation was catalysed by a 2022 study published in the Journal of the National Cancer Institute, drawn from the National Institutes of Health Sister Study. Because the figures are frequently distorted in both directions, they are worth stating precisely.

Researchers followed 33,497 US women aged 35 to 74 for nearly 11 years, during which 378 uterine cancer cases were diagnosed. Women who reported frequent hair straightener use — more than four times in the previous year — were more than twice as likely to develop uterine cancer than women who did not use the products.

The absolute figures matter as much as the relative risk. The researchers estimated that 1.64% of women who never used hair straighteners would develop uterine cancer by age 70, rising to 4.05% among frequent users. That is a real and meaningful increase. It is also not the same as a majority of users developing cancer, and any source implying otherwise is misrepresenting the study.

About 60% of the participants who reported using straighteners self-identified as Black women, reflecting product use patterns rather than differing biological risk — the study found no race-specific difference in the relationship between use and cancer incidence. This is central to the claims, because it shapes who was exposed most heavily and most often.

The Only Money Currently Allocated

One figure circulates in connection with hair relaxer claims and should be understood correctly. In connection with Revlon’s bankruptcy, a reserve reported at approximately $44 million was set aside in relation to talc and hair relaxer claims.

That is a bankruptcy reserve for one defendant, not a settlement of the MDL. Divided across a claimant population in the tens of thousands, it does not indicate individual claim value, and it does not bind the other manufacturers named in the litigation. It is the only allocated fund currently associated with these claims, and it is not a compensation programme.

Why Quoted Hair Relaxer Settlement Amounts Are Projections

Hair relaxer settlement amounts appear widely across legal marketing sites, often presented with a precision the underlying record cannot support. There is no settlement, no verdict, and no published matrix, so every such range is a model — typically built by analogy to talc and other hormone-sensitive cancer litigations.

That does not make the exercise worthless. Analogous litigation is genuinely informative about how claims get grouped, and about which evidence separates a strong claim from a weak one. It does mean that a specific dollar figure attached to a hair relaxer claim in 2026 is an estimate about a future that has not happened yet, and it should be read that way.

TortAdvisor does not publish a projected hair relaxer payout figure, because there is no defensible basis for one until the 2027 bellwethers return results.

Factors That Will Affect Claim Value

When valuation does become possible, these are the variables that will drive it — and they are worth documenting now, while records are easier to obtain:

• Diagnosis — uterine and endometrial cancer claims sit at the centre of the litigation; ovarian cancer and fibroid claims occupy different positions.
• Duration and frequency of use — the Sister Study finding turned on frequent use over years, so a long, consistent use history matters.
• Age at first use — earlier and longer exposure strengthens the causal narrative.
• Product identification — naming brands used, and ideally retaining purchase history, is one of the hardest evidentiary problems in this litigation because these were everyday consumer purchases.
• Medical documentation — pathology, staging, surgical history including hysterectomy, and treatment records.
• Alternative risk factors — defendants will point to obesity, family history, genetics and other contributors, and the strength of a claim depends partly on how cleanly those can be addressed.
• Economic loss — treatment costs, lost earnings and future care.

Who Qualifies

Claims generally involve a diagnosis of uterine cancer, endometrial cancer, ovarian cancer or uterine fibroids, following regular use of chemical hair relaxers or straighteners over an extended period, brought within the applicable state limitation period.

Limitation periods run from diagnosis or from discovery of the connection between the product and the injury, and they vary considerably between states. Because the litigation is pretrial rather than closed, claims can still be filed — but the deadline analysis is individual and time-sensitive.

Timeline: What Happens Next

The sequence to watch is straightforward. Daubert and summary-judgment rulings are expected to follow the November 2026 motion deadline. If the plaintiffs’ general-causation experts survive that challenge, the three selected bellwether cases proceed toward trial in 2027. Those verdicts — win or lose, and whatever the amounts — are what give both sides a basis to negotiate.

Settlement discussions in mass torts of this size generally follow bellwether results rather than preceding them. A realistic expectation is that meaningful settlement information emerges after the first trials, not before.

Use the Hair Relaxer Settlement Calculator

Our free Hair Relaxer Settlement Calculator helps organise the use history, diagnosis and documentation an attorney will ask for. It produces an educational estimate based on the factors above — not a settlement figure, because none exists.

How a Hair Relaxer Settlement Would Actually Be Paid

No hair relaxer settlement exists, so no claimant has been paid anything through MDL 3060. It is still worth understanding the mechanism, because when a matrix does appear it will be reported as a set of gross figures, and the difference between those and what reaches a claimant is substantial.

Mass tort settlements of this size are administered through a qualified settlement fund. Each claim is scored against a matrix — typically cancer type and stage, age at diagnosis, documented product use, and treatment burden — and assigned a gross allocation. From that come the contingency fee and case expenses set out in the retainer agreement, then repayment of medical liens.

Liens matter disproportionately here. Uterine, endometrial and ovarian cancer treatment is expensive, and whoever paid for it — a private insurer, Medicare or Medicaid — has a right to be reimbursed out of the settlement. Those amounts can often be reduced through formal lien resolution, but the process adds months.

The practical consequence is that when hair relaxer settlement amounts are eventually published, a claimant should read them as gross figures and expect the net to be materially lower. Anyone quoting a net figure today is guessing twice over: once about the matrix, and once about the deductions.

What to Gather Before Speaking to a Lawyer

The distinctive difficulty in hair relaxer cases is proving exposure. There is no implant record and no prescription history. What matters is which products were used, how often, and for how long — and that evidence lives in memory, receipts and salon records rather than in a medical file.

Starting early matters. Loyalty-card purchase histories from pharmacies and beauty retailers can often be retrieved on request, salons may hold appointment and service records going back years, and a stylist may be willing to provide a statement. Reconstructing two decades of use from memory alone is possible but far weaker than documentation.

On the medical side, the essential records are the pathology report confirming the diagnosis, the treatment history including any hysterectomy, chemotherapy or radiation, and follow-up records establishing ongoing effects. Claimants should also expect the defence to raise alternative risk factors — family history, body mass index, hormone therapy, reproductive history — and should be candid about them. None of these disqualifies a claim; concealing them weakens one.

Limitation periods vary by state and generally run from diagnosis or from the point at which the connection to the product could reasonably have been discovered. They do not pause because the litigation has not reached trial.

Common Misconceptions About Hair Relaxer Settlement Amounts

“Settlements are expected in 2026, so payouts are close.”

Bellwether fact discovery closed in June 2026 and expert challenges are due in November 2026. Trials are expected in 2027, and settlement discussions in mass torts of this size generally follow bellwether verdicts rather than preceding them. Any 2026 payout date is a forecast, and this litigation has already outrun several.

“The $300,000 to $1.5 million tiers show what claims are worth.”

Those tiers appear on numerous legal marketing sites and are models, not terms. They are built by analogy to talc and other hormone-sensitive cancer litigations. No hair relaxer case has been settled or tried, so there is nothing for the models to be calibrated against. TortAdvisor publishes no projected hair relaxer settlement amounts for that reason.

“The Sister Study proves hair relaxers cause cancer.”

The 2022 NIH Sister Study found an association, not causation: among 33,497 women followed for roughly eleven years, uterine cancer occurred in about 1.64% of women who never used straighteners and about 4.05% of frequent users. That is a meaningful signal and it is why this litigation exists. It is not the same as proof in an individual case, and the November 2026 expert challenges exist precisely to test how far it can be taken.

“Revlon’s bankruptcy money is the hair relaxer settlement.”

It is not. The reserve set aside in Revlon’s bankruptcy is the only money currently allocated anywhere in this litigation, it covers talc as well as hair relaxer claims, and it is a bankruptcy reserve rather than a settlement of the MDL. The other defendants have set aside nothing that has been made public.

“A bigger docket means a bigger payout.”

Docket size drives the total a defendant may eventually pay; it does not drive what an individual claim is worth, and in some litigations it pushes individual figures down. A larger claim pool spread across the same corporate balance sheet means each claim competes for a share of a finite amount. The relevant comparison is not how many hair relaxer cases have been filed, but how many are well documented enough to hold their value once a matrix exists.

“I can file later, once settlements are announced.”

Waiting is the most expensive mistake available in this litigation. Limitation periods run on their own schedule regardless of where the MDL has got to, and in most states they began at diagnosis or at the point the link to the product could reasonably have been discovered. A claim that expires before a matrix is published is worth nothing, however strong its facts.

Frequently Asked Questions

What is the average hair relaxer settlement amount?

There is no average, because no hair relaxer case has settled or been tried. Every set of hair relaxer settlement amounts published so far is modelled, not paid. Any figure presented as an average is a projection modelled on other litigation. The first bellwether trials in MDL 3060 are expected in 2027.

Has there been a hair relaxer settlement?

No global settlement has been announced and no compensation matrix has been published. The only allocated money associated with these claims is a bankruptcy reserve reported at approximately $44 million in connection with Revlon, which covers talc and hair relaxer claims and is not an MDL settlement.

Have any hair relaxer cases gone to trial?

No. Three bellwether cases have been selected, bellwether fact discovery closed in June 2026, and Daubert and summary-judgment motions are due in November 2026. First trials are broadly expected in 2027.

Does using hair relaxer mean I will get uterine cancer?

No. The NIH Sister Study estimated that 1.64% of women who never used straighteners would develop uterine cancer by age 70, compared with 4.05% of frequent users. That is roughly a doubling of risk, but the large majority of users in the study did not develop uterine cancer.

Can I still file a hair relaxer claim?

Yes — and filing now does not depend on hair relaxer settlement amounts being known, since eligibility is assessed on use history and diagnosis. The litigation is active and accepting claims, but limitation periods vary by state and generally run from diagnosis or from discovery of the link between the product and the injury. The analysis is individual, so timing matters.

Sources

The litigation status and scientific findings on this page come from federal court records and primary research. No settlement figure is stated on this page because none has been published.

• Judicial Panel on Multidistrict Litigation — Pending MDL Dockets — source for MDL 3060 pending action counts.
• National Institutes of Health — Hair straightening chemicals associated with higher uterine cancer risk — source for the Sister Study cohort, follow-up and absolute risk figures.
• Chang, O’Brien & White, Journal of the National Cancer Institute (2022) — the underlying peer-reviewed study.
• U.S. District Court, Northern District of Illinois — the court administering MDL 3060 before Judge Mary M. Rowland.
• U.S. Food and Drug Administration — Hair Smoothing Products That Release Formaldehyde — federal regulatory background on chemical straighteners.

Related Hair Relaxer Resources

• Hair Relaxer Lawsuit — eligibility, injuries and how claims are filed.
• Hair Relaxer Settlement Calculator — organise your use history and diagnosis.
• Dangerous Drug & Product Liability Lawsuits — other active product claims.
• Settlement Amounts — payout guides across all case types.

About the Author

Mason Arnao is a legal content strategist and mass tort researcher at TortAdvisor.com. He covers emerging litigation, settlement trends, and consumer legal rights across pharmaceutical, product liability, and personal injury law.